Neogenomics (NEO) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$159.6 million.
- Neogenomics' Enterprise Value rose 5873.84% to -$159.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$159.6 million, marking a year-over-year increase of 5873.84%. This contributed to the annual value of -$159.6 million for FY2025, which is 5873.84% up from last year.
- Neogenomics' Enterprise Value amounted to -$159.6 million in Q4 2025, which was up 5873.84% from -$164.1 million recorded in Q3 2025.
- In the past 5 years, Neogenomics' Enterprise Value ranged from a high of -$159.6 million in Q4 2025 and a low of -$802.7 million during Q1 2021
- In the last 5 years, Neogenomics' Enterprise Value had a median value of -$412.3 million in 2023 and averaged -$415.0 million.
- Per our database at Business Quant, Neogenomics' Enterprise Value crashed by 83060.03% in 2021 and then surged by 5873.84% in 2025.
- Over the past 5 years, Neogenomics' Enterprise Value (Quarter) stood at -$515.4 million in 2021, then grew by 15.02% to -$438.0 million in 2022, then grew by 5.2% to -$415.2 million in 2023, then rose by 6.83% to -$386.8 million in 2024, then surged by 58.74% to -$159.6 million in 2025.
- Its Enterprise Value was -$159.6 million in Q4 2025, compared to -$164.1 million in Q3 2025 and -$163.7 million in Q2 2025.